European Journal of Clinical Pharmacology

, Volume 63, Issue 11, pp 983–984 | Cite as

Drug-related risks

Editorial Commentary

References

  1. 1.
    Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMedCrossRefGoogle Scholar
  2. 2.
    Tanne JH (2007) FDA places “black box” warning on antidiabetes drugs. Br Med J 334:1237CrossRefGoogle Scholar
  3. 3.
    Drazen JM, Morrissey S, Curfman GD (2007) Rosiglitazone—continued uncertainty about safety. N Engl J Med 357:63–64PubMedCrossRefGoogle Scholar
  4. 4.
    Nathan DM (2007) Rosiglitazone and cardiotoxicity—weighting the evidence. N Engl J Med 357:64–66PubMedCrossRefGoogle Scholar
  5. 5.
    Psaty BM, Furberg CD (2007) The record on rosiglitazone and the risk of myocardial infarction. N Eng J Med 357:64–69CrossRefGoogle Scholar
  6. 6.
    Howard RL, Avery AJ, Slavenburg S et al (2007) Which drugs cause preventable admissions to hospitals? A systematic review. Br J Clin Pharmacol 63:136–147PubMedCrossRefGoogle Scholar
  7. 7.
    Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J (2001) Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol 56:935–941PubMedCrossRefGoogle Scholar
  8. 8.
    Heilmann K (2002) Das Risiko der Sicherheit. Hirzel, StuttgartGoogle Scholar
  9. 9.
    Wilson R, Crouch EA (1987) Risk assessment and comparisons: an introduction. Science 236:267–270PubMedCrossRefGoogle Scholar
  10. 10.
    Gislason GH, Jacobsen S, Rasmussen JN et al (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 113:2906–2913PubMedCrossRefGoogle Scholar
  11. 11.
    Lagerqvist B, James SK, Stenestrand U et al (2007) Long-term outcome with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009–1019PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Dr. Margarete Fischer-Bosch Institute of Clinical PharmacologyStuttgartGermany
  2. 2.University of TübingenTübingenGermany

Personalised recommendations